132 related articles for article (PubMed ID: 18976118)
1. Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2.
Mintz A; Gibo DM; Madhankumar AB; Cladel NM; Christensen ND; Debinski W
Cancer Biother Radiopharm; 2008 Oct; 23(5):581-9. PubMed ID: 18976118
[TBL] [Abstract][Full Text] [Related]
2. A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors.
Kim JW; Young JS; Solomaha E; Kanojia D; Lesniak MS; Balyasnikova IV
Sci Rep; 2015 Dec; 5():18133. PubMed ID: 26656559
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-13 receptor alpha 2 as a marker of poorer prognosis in high-grade astrocytomas.
Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Otsuka Y; Yamaguchi M; Ohnishi H; Ohtaki S; Noshiro S; Ookawa S; Mikami T; Mikuni N; Honmou O
J Neurosurg Sci; 2018 Jun; 62(3):239-244. PubMed ID: 28079349
[TBL] [Abstract][Full Text] [Related]
4. IL-13 receptor-directed cancer vaccines and immunotherapy.
Nakashima H; Husain SR; Puri RK
Immunotherapy; 2012 Apr; 4(4):443-51. PubMed ID: 22512637
[TBL] [Abstract][Full Text] [Related]
5. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2.
Balyasnikova IV; Wainwright DA; Solomaha E; Lee G; Han Y; Thaci B; Lesniak MS
J Biol Chem; 2012 Aug; 287(36):30215-27. PubMed ID: 22778273
[TBL] [Abstract][Full Text] [Related]
6. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
[TBL] [Abstract][Full Text] [Related]
7. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
[TBL] [Abstract][Full Text] [Related]
8. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma.
Mintz A; Gibo DM; Madhankumar AB; Debinski W
J Neurooncol; 2003; 64(1-2):117-23. PubMed ID: 12952292
[TBL] [Abstract][Full Text] [Related]
9. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
[TBL] [Abstract][Full Text] [Related]
10. A Novel Recombinant Modified Vaccinia Ankara Virus expressing Interleukin-13 Receptor α2 Antigen for Potential Cancer Immunotherapy.
Sato Y; Vatsan R; Joshi BH; Husain SR; Puri RK
Curr Mol Med; 2023 Mar; ():. PubMed ID: 36999709
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of the alpha2 chain of the interleukin-13 receptor in metastatic human prostate cancer ARCaPM cells.
He H; Xu J; Nelson PS; Marshall FF; Chung LW; Zhau HE; He D; Wang R
Prostate; 2010 Jun; 70(9):993-1001. PubMed ID: 20166133
[TBL] [Abstract][Full Text] [Related]
12. An IL13Rα2 peptide exhibits therapeutic activity against metastatic colorectal cancer.
Bartolomé RA; Jaén M; Casal JI
Br J Cancer; 2018 Oct; 119(8):940-949. PubMed ID: 30318506
[TBL] [Abstract][Full Text] [Related]
13. An MSN-PEG-IP drug delivery system and IL13Rα2 as targeted therapy for glioma.
Shi J; Hou S; Huang J; Wang S; Huan W; Huang C; Liu X; Jiang R; Qian W; Lu J; Wang X; Shi W; Huang R; Chen J
Nanoscale; 2017 Jul; 9(26):8970-8981. PubMed ID: 28443896
[TBL] [Abstract][Full Text] [Related]
14. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
Hegde M; Mukherjee M; Grada Z; Pignata A; Landi D; Navai SA; Wakefield A; Fousek K; Bielamowicz K; Chow KK; Brawley VS; Byrd TT; Krebs S; Gottschalk S; Wels WS; Baker ML; Dotti G; Mamonkin M; Brenner MK; Orange JS; Ahmed N
J Clin Invest; 2016 Aug; 126(8):3036-52. PubMed ID: 27427982
[TBL] [Abstract][Full Text] [Related]
15. Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis.
Brown CE; Warden CD; Starr R; Deng X; Badie B; Yuan YC; Forman SJ; Barish ME
PLoS One; 2013; 8(10):e77769. PubMed ID: 24204956
[TBL] [Abstract][Full Text] [Related]
16. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
17. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
[TBL] [Abstract][Full Text] [Related]
18. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.
Thaci B; Brown CE; Binello E; Werbaneth K; Sampath P; Sengupta S
Neuro Oncol; 2014 Oct; 16(10):1304-12. PubMed ID: 24723564
[TBL] [Abstract][Full Text] [Related]
19. A novel target anti-interleukin-13 receptor subunit alpha-2 monoclonal antibody inhibits tumor growth and metastasis in lung cancer.
Raza G; Yunus FU; Mangukiya HB; Merugu SB; Mashausi DS; Zeling W; Negi H; Zhou B; Roy D; Wu Z; Li D
Int Immunopharmacol; 2021 Jan; 90():107155. PubMed ID: 33243603
[TBL] [Abstract][Full Text] [Related]
20. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
Brown CE; Starr R; Aguilar B; Shami AF; Martinez C; D'Apuzzo M; Barish ME; Forman SJ; Jensen MC
Clin Cancer Res; 2012 Apr; 18(8):2199-209. PubMed ID: 22407828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]